Arthroscopic Debridement of the Knee: OHTAC Recommendation

Similar documents
Point-of-Care Hemoglobin A1c Testing: OHTAC Recommendation

Aspartate Aminotransferase Testing in Community-Based Laboratories: An Expert Consultation

Parathyroid Hormone: An Expert Consultation

Arthroscopic Debridement of the Knee: An Evidence Update

End-of-Life Care Interventions: An Economic Analysis

OHTAC Recommendation. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer

OHTAC Recommendation

OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee

OHTAC Recommendation

Proposed Strategy for Epilepsy Care in Ontario

Introduction to the POWER Study Chapter 1

Arthroscopic Lavage and Debridement for Osteoarthritis of the Knee

OHTAC Recommendation: Chronic Obstructive Pulmonary Disease (COPD) Ontario Health Technology Advisory Committee

OHTAC Recommendation

Antibiotic-Laden Bone Cement for Primary Knee Arthroplasty: A Rapid Review

Simultaneous or Staged Bilateral Knee Arthroplasty: A Rapid Review

Criteria for Referral to Heart Failure Clinics: A Rapid Review

Quality-Based Procedures: Clinical Handbook for Primary Hip and Knee Replacement

Patient Involvement in Drug Coverage Review Ontario Public Drug Programs Patient Evidence Submissions

1. Develop research question Develop PICOS in consultation with experts, end users, applicant, etc.

Technologies for Osteoarthritis of the Knee

Quality-Based Procedures: Clinical Handbook for Degenerative Disorders of the Shoulder

Quality-Based Procedures: Clinical Handbook for Stroke (Acute and Postacute)

Victorian Model of Care for Osteoarthritis of the Hip and Knee

Regional Clinical Co-Lead (Physician) Role Opportunity

WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 611/16

pan-canadian Oncology Drug Review Final Economic Guidance Report Crizotinib (Xalkori) Resubmission for Advanced Non-Small Cell Lung Cancer

Ontario Stroke Network Provincial Integrated Working Group: Rehabilitation Intensity- FINAL REPORT

OHTAC Recommendation. Endovascular Laser Treatment for Varicose Veins. Presented to the Ontario Health Technology Advisory Committee in November 2009

Clinical Utility of Serologic Testing for Celiac Disease in Asymptomatic Patients

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Advanced or Metastatic Non-Small Cell Lung Cancer

Priorities Forum Statement GUIDANCE

Management of the Early Degenerate Knee. Kieran Barnard Hip and Knee Pathway Lead

OHTAC Recommendation: Internet- Based Device-Assisted Remote Monitoring of Cardiovascular Implantable Electronic Devices

pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018

Prostate-Specific Antigen (PSA) Based Population Screening for Prostate Cancer: An Economic Analysis

Knee Arthoscopy with or without Debridement Policy CRITERIA BASED ACCESS

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

VIOLENCE PREVENTION ALLIANCE TERMS OF REFERENCE

Cost-effectiveness of the Carbon-13 Urea Breath Test for the Detection of Helicobacter Pylori: An Economic Analysis

Optimal Treatment Strategies for Localized Ewing s Sarcoma of Bone after Neoadjuvant Chemotherapy

Humber. Arthroscopy Knee

pan-canadian Oncology Drug Review Final Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer January 4, 2019

Cochrane Musculoskeletal Group: Plain Language Summary (PLS) Guide for Authors

Action Plans for Individuals with Chronic Obstructive Pulmonary Disease (COPD): A Rapid Review

July 22, The Smoking Cessation Initiative Description- A Multi-Prong Approach: 1. RNAO Smoking Cessation (SC) Coordinators

ONTARIO CANCER PLAN

Update on the Canadian Food Inspection Agency (CFIA) Food Labelling Modernization Initiative

Specialized Multidisciplinary Community-Based Care Series

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis

pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017

OHTAC Recommendation

pan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016

Ministry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW

This document is a preview generated by EVS

Negative Pressure Wound Therapy

Palliative Care Quality Standard: Guiding Evidence-Based, High-Quality Palliative Care in Ontario Presented by: Lisa Ye, Lead, Quality Standards,

NHS Birmingham and Solihull Clinical Commissioning Group. DRAFT Policy for Knee Arthroscopy for Degenerative Knee Disease

pan-canadian Oncology Drug Review Final Economic Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016

CIHRT Exhibit P-2592 Page 1 APPENDIX. ADAPTE Process for the Treatment of In situ Breast Carcinoma. Eastern Health Breast Disease Site Group

ISO INTERNATIONAL STANDARD. Dentistry Periodontal curettes, dental scalers and excavators Part 2: Periodontal curettes of Gr-type

DEMENTIA. Best Practice Guidance for Ambulance Services

Best Care for patients with Knee pain

15 May 2017 Exposure Draft. Response Due Date 23 June Exposure Draft

New Evidence Suggests that Work Related Knee Pain with Degenerative Complications May Not Require Surgery

Surgical Services. Chapter

DECISION NO. 2870/16

pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018

Screening Mammography for Women Aged 40 to 49 Years at Average Risk for Breast Cancer

Non-Surgical vs. Surgical Treatment of Meniscus Tears of the Knee

CENTRAL LHIN CEO REPORT CORRESPONDENCE

Provincial Cancer Control Advisory Committee

AdvaMed Medtech Value Assessment Framework in Practice

10.2 Summary of the Votes and Considerations for Policy

Meniscus Tears. Three bones meet to form your knee joint: your thighbone (femur), shinbone (tibia), and kneecap (patella).

Introduction of Innovation into an Activity-Based Funding System in Ontario Stroke Endovascular Treatment (EVT)

Goals and Objectives for the Orthopaedic Surgery Resident McGill Orthopaedic Sports Medicine and Minimally Invasive (MGH & Shriners) Junior Residents

pan-canadian Oncology Drug Review Final Economic Guidance Report Ibrutinib (Imbruvica) for Mantle Cell Lymphoma July 19, 2016

Ontario s Narcotics Strategy

Infectious Diseases-HAI Idaho Department of Health and Welfare, Division of Public Health Boise, Idaho. Assignment Description

The development of the Central West Tobacco Control Area Network s system of local tobacco cessation communities of practice: Appendices A - C

Making EvidEncE RElEvant on ta R i o he a lt h t Ec hno logy a dv isory c omm i t t EE & t he MEdic a l a dv isory secre ta R i at

pan-canadian Oncology Drug Review Initial Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer May 5, 2016

ADULT IMMUNIZATION QUALITY IMPROVEMENT BEST PRACTICES COLLABORATIVE Applications are due by close of business (5:30pm, PDT), October 24, 2014

Hip Arthroscopy Criteria Based Access Protocol Supporting people in Dorset to lead healthier lives

pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015

Terms of Reference. Tripartite Planning Committee for First Nations & Aboriginal Maternal & Child Health

Road Home Program: Center for Veterans and Their Families at Rush. Philip Held, Ph.D. Research Director

Issue Paper: Monitoring a Rights based Approach: Key Issues and Suggested Approaches

PROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary

NATIONAL SURVEILLANCE OF OSTEOARTHRITIS AND RHEUMTOID ARTHRITIS IN CANADA

Improving Access to High Quality Hospice Palliative Care

MEMORANDUM OF UNDERSTANDING THE INDEPENDENT FUNDRAISING STANDARDS & ADJUDICATION PANEL FOR SCOTLAND AND THE FUNDRAISING REGULATOR

Cancer Service Performance Indicators Round 1 Report. Integrated Cancer Services. January Department of Health

Patient Reference Guide. Osteoarthritis. Care for Adults With Osteoarthritis of the Knee, Hip, or Hand

There are no financial implications arising from this report.

What Is Spinal Stenosis?

Alaska Mental Health Board & Advisory Board on Alcoholism

Transcription:

Arthroscopic Debridement of the Knee: OHTAC Recommendation Ontario Health Technology Advisory Committee November 2014 Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12

Suggested Citation This report should be cited as follows: Ontario Health Technology Advisory Committee (OHTAC). Arthroscopic debridement of the knee: OHTAC recommendation [Internet]. Toronto: Queen's Printer for Ontario; 2014 November. 12 p. Available from: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/ontario-health-technology-assessmentseries/arthroscopic-debridement-update Permission Requests All inquiries regarding permission to reproduce any content in Health Quality Ontario reports should be directed to EvidenceInfo@hqontario.ca. How to Obtain OHTAC Recommendation Reports From Health Quality Ontario All OHTAC reports are freely available in PDF format at the following URL: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/ohtac-recommendations. Conflict of Interest Statement All authors in the Evidence Development and Standards branch at Health Quality Ontario are impartial. There are no competing interests or conflicts of interest to declare. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 2

About Health Quality Ontario Health Quality Ontario (HQO) is an arms-length agency of the Ontario government. It is a partner and leader in transforming Ontario s health care system so that it can deliver a better experience of care, better outcomes for Ontarians, and better value for money. Health Quality Ontario strives to promote health care that is supported by the best available scientific evidence. The Evidence Development and Standards branch works with advisory panels, clinical experts, developers of health technologies, scientific collaborators, and field evaluation partners to provide evidence about the effectiveness and cost-effectiveness of health interventions in Ontario. To conduct its systematic reviews of health interventions, the Evidence Development and Standards branch examines the available scientific literature, making every effort to consider all relevant national and international research. If there is insufficient evidence on the safety, effectiveness, and/or cost-effectiveness of a health intervention, HQO may request that its scientific collaborators conduct economic evaluations and field evaluations related to the reviews. Field evaluation partners are research institutes focused on multicentred clinical trials and economic evaluation, as well as institutes engaged in evaluating the safety and usability of health technologies. About the Ontario Health Technology Advisory Committee The Ontario Health Technology Advisory Committee (OHTAC) is a standing advisory subcommittee of the Board of Directors of Health Quality Ontario. Based on the evidence provided by Evidence Development and Standards and its partners, OTHAC makes recommendations about the uptake, diffusion, distribution, or removal of health interventions within the provincial health system. When making its recommendations, OHTAC applies a unique decision-determinants framework that takes into account overall clinical benefit, value for money, societal and ethical considerations, and the economic and organizational feasibility of the health care intervention in Ontario. Publishing Health Quality Ontario Research When the evidence development process is nearly completed, draft reviews, reports, and OHTAC recommendations are posted on HQO s website for 21 days for public and professional comment. For more information, please visit: http://www.hqontario.ca/evidence/evidence-process/evidence-review-process/professional-and-public-engagementand-consultation. Once finalized and approved by the Board of Directors of Health Quality Ontario, the research is published as part of the Ontario Health Technology Assessment Series, which is indexed in MEDLINE/PubMed, Excerpta Medica/Embase, and the Centre for Reviews and Dissemination database. Corresponding OHTAC recommendations and associated reports are also published on the HQO website. Visit http://www.hqontario.ca for more information. When sufficient data are available, OHTAC tracks the ongoing use of select interventions it has previously reviewed, compiling data by time period and region. The results are published in the Ontario Health Technology Maps Project Report. Disclaimer This report was prepared by the Evidence Development and Standards branch at Health Quality Ontario or one of its research partners for the Ontario Health Technology Advisory Committee and was developed from analysis, interpretation, and comparison of scientific research. It also incorporates, when available, Ontario data and information provided by experts and applicants to HQO. The analysis may not have captured every relevant publication and relevant scientific findings may have been reported since the development of this recommendation. This report may be superseded by an updated publication on the same topic. Please check the Health Quality Ontario website for a list of all publications: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 3

Table of Contents Background... 5 Conclusions... 6 Decision Determinants... 7 OHTAC Recommendations... 8 Appendices... 9 Appendix 1: Decision Determinants... 9 References... 11 Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 4

Background The Evidence Development and Standards branch at Health Quality Ontario conducted an evidence-based analysis update 1 of the 2005 report titled Arthroscopic Lavage and Debridement for Osteoarthritis of the Knee. (1) The updated report (2) answered the following research question: What is the effectiveness of arthroscopic debridement with or without meniscectomy for patients with osteoarthritis of the knee or with meniscal injury from degenerative causes? This update was the result of an expert advisory panel consulted for work on developing an episode of care for the HQO clinical handbook on arthroscopic debridement (3) informing Health Quality Ontario of new evidence being published in the area of arthroscopic debridement since the original evidence-based analysis in 2005. This expert advisory panel was consulted throughout the course of the project. 1 Evidence update: Evidence updates are conducted upon request when new evidence is published that changes the findings of a previous HQO analysis. The evidence could provide new information on the safety, efficacy, effectiveness, or cost-effectiveness of the intervention, or it could provide higher-quality evidence, thereby increasing confidence in the findings. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 5

Conclusions The updated report on arthroscopic debridement of the knee (2) concluded the following: Moderate-quality evidence shows no significant difference in pain or functional status among patients with osteoarthritis of the knee or degenerative causes of meniscal injury who received arthroscopic debridement with or without meniscectomy compared with placebo (sham surgery). Low-quality evidence shows no significant difference in pain or functional status among patients with osteoarthritis of the knee or degenerative causes of meniscal injury who received arthroscopic debridement with or without meniscectomy compared with usual care (physical therapy). Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 6

Decision Determinants OHTAC has developed a decision-making framework that consists of 7 guiding principles for decision making and a decision determinants tool. When making a decision, OHTAC considers 4 explicit main criteria: overall clinical benefit, consistency with expected societal and ethical values, value for money, and feasibility of adoption into the health system. For more information on the decision-making framework, please refer to the Decision Determinants Guidance document available at: http://www.hqontario.ca/evidence/evidence-process/evidence-review-process/decision-makingframework. Appendix 1 provides a summary of the decision determinants for this recommendation. On the basis of the decision determinants criteria, OHTAC weighted in favour of the criteria on the evidence. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 7

OHTAC Recommendations OHTAC recommends against arthroscopic debridement for patients with uncomplicated (without meniscal tears) osteoarthritis of the knee. OHTAC also recommends against arthroscopic surgery as a first line of treatment for patients with degenerative meniscal tears with or without osteoarthritis. However, OHTAC recommends a field evaluation be conducted to determine the clinical effectiveness and cost effectiveness of arthroscopic meniscectomy as an alternative to ongoing nonsurgical management (e.g., physical therapy) for patients who do not improve sufficiently after an initial 6-month period of nonsurgical management. Pending the results of the field evaluation, OHTAC recommends that, if nonsurgical treatment for at least 6 months fails, arthroscopic meniscectomy be considered. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 8

Appendices Appendix 1: Decision Determinants Table A1: Decision Determinants for Knee Arthroscopy for Osteoarthritis of the Knee or Degenerative Causes of Meniscal Injury Decision Criteria Subcriteria Decision Determinants Considerations Overall clinical benefit How likely is the health technology/intervention to result in high, moderate, or low overall benefit? Consistency with expected societal and ethical values a How likely is adoption of the health technology/intervention to be congruent with societal and ethical values? Value for money How efficient is the health technology likely to be? Effectiveness How effective is the health technology/intervention likely to be (taking into account any variability)? Safety How safe is the health technology/intervention likely to be? Burden of illness What is the likely size of the burden of illness pertaining to this health technology/intervention? Need How large is the need for this health technology/intervention? Societal values How likely is the adoption of the health technology/intervention to be congruent with expected societal values? Ethical values How likely is the adoption of the health technology/intervention to be congruent with expected ethical values? Economic evaluation How efficient is the health technology/intervention likely to be? There is no evidence of superiority of arthroscopic debridement with or without meniscectomy for OA of the knee or degenerative meniscal injury, versus placebo (sham surgery) or usual care (physical therapy). (2) Arthroscopy is a simple outpatient procedure with minimal recovery. Patients undergoing arthroscopy face little risk from infection or from complications of anesthesia. Estimated incidence of OA of the knee in Ontario is about 16,000 (130 per 100,000 people aged 45 64); the prevalence is 125,000. (1) 68.4% of arthroscopies currently conducted in Ontario are for OA or degenerative knee injury (Based on FY 20012/2013). (3) TKRs, or alternatives such as physical therapy, are not easily accessible to all patients because of geography and time and financial constraints. Experts report that patients have subjective improvements in pain and function after receiving arthroscopic knee surgery. Some patients prefer arthroscopy, because TKRs have longer recovery times and because alternatives such as physical therapy may not be easily accessible. Experts report that MRIs capture meniscal tears in every arthritic knee, which can lead to unnecessary arthroscopic procedures in unsuitable patients. There is currently potential bias in the remuneration and available operating room time in Ontario. Experts report that hospitals cap the number of TKRs surgeons can conduct per year but not the number of arthroscopic surgeries. There are ethical concerns with providing surgery that has no evidence of superiority over less invasive alternatives. However, there are also ethical concerns about denying patients access to a potentially effective treatment. No economic evaluation was conducted. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 9

Decision Criteria Subcriteria Decision Determinants Considerations Feasibility of adoption into health system How feasible is it to adopt the health technology/intervention into the Ontario health care system? Economic feasibility How economically feasible is the health technology/intervention? Organizational feasibility How organizationally feasible is it to implement the health technology/intervention? Knee arthroscopic surgeries are currently conducted and funded in Ontario. Abbreviations: MRI, magnetic resonance imaging; OA, osteoarthritis; TKR, total knee replacement. a Anticipated or assumed common ethical and societal values held in regard to the target condition, target population, or treatment options. Unless scientific sources describe ethical and societal values, expected values are considered. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 10

References (1) Medical Advisory Secretariat. Arthroscopic lavage and debridement for osteoarthritis of the knee: an evidence-based analysis. Ont Health Technol Assess Ser. 2005;5(12):1-37. Available from: http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/ontario-healthtechnology-assessment-series/arthroscopic-lavage-and-debridement. Accessed November 18, 2014. (2) Evidence Development and Standards Branch, Health Quality Ontario. Arthroscopic debridement of the knee: an evidence update. Ont Health Technol Assess Ser [Internet]. 2014 November; 14(13):1 43. Available from: http://www.hqontario.ca/evidence/publications-and-ohtacrecommendations/ontario-health-technology-assessment-series/arthroscopic-debridement-update. Accessed November 18, 2014. (3) Health Quality Ontario; Ministry of Health and Long-Term Care. Quality-based procedures: Clinical handbook for knee arthroscopy. Toronto: Health Quality Ontario; 2014 August. 68 p. Available from: http://www.hqontario.ca/evidence/evidence-process/episodes-of-care#kneearthroscopy. Accessed November 18, 2014. Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 11

Health Quality Ontario 130 Bloor Street West, 10 th Floor Toronto, Ontario M5S 1N5 Tel: 416-323-6868 Toll Free: 1-866-623-6868 Fax: 416-323-9261 Email: EvidenceInfo@hqontario.ca www.hqontario.ca Queen s Printer for Ontario, 2014 Arthroscopic Debridement of the Knee: OHTAC Recommendation. November 2014; pp. 1 12 12